Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study…
Time to educate patients about biosimilars?
March 22, 2023 Today, the U.S. Food and Drug Administration released new educational materials for patients related to biosimilars and…
Stuart Schlossman
Are you on a Biologic Medication? What you need to know about biosimilar treatment options.
—————– Vea esta página en español The Food and Drug Administration (FDA) has approved many biologics (also called biological products),…
Stuart Schlossman
FDA Approves Tascenso ODT® (fingolimod), similar to Gilenya, for Relapsing MS
February 21, 2023 The U.S. Food and Drug Administration recently approved Tascenso ODT® (fingolimod, Cycle Pharmaceuticals) as an orally disintegrating tablet…
Stuart Schlossman
Favorable Safety Outcomes Observed in Ozanimod (#Zeposia) Over Diroximel Fumarate (Vumerity)
Feb 26, 2023 – Marco Meglio – #ACTRIMS Conferences: Americas Committee for Treatment and Research in Multiple Sclerosis…
Stuart Schlossman
BTK Inhibitor Evobrutinib Displays Superior Efficacy Compared With Anti-CD20 Treatment for MS
Feb 25, 2023 – Isabella Ciccone, MPH A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized…
Stuart Schlossman
Zeposia’s long-term use doesn’t affect heart health, Phase 3 trials show
by Andrea Lobo, PhD | February 14, 2023 No major heart rate or echocardiogram changes over year or more of…
Stuart Schlossman
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, MD1; Heinz Wiendl, MD2; Karsten Roth, PhD3; et al Hendrik Wessels, PhD3; Josef Höfler, PhD4; Cyrill Hornuss, MD5; Bernd Liedert, PhD5; Krzysztof Selmaj, MD, PhD6 Author Affiliations Article Information JAMA Neurol. Published online January 23, 2023. doi:10.1001/jamaneurol.2022.5007 Key Points Question Does proposed biosimilar…
Stuart Schlossman
• Learning about Visual Disturbances in MS
Event date: August 27th / Published Date: September 21, 2022 Listen with Dr. Jonathan Calkwood’s In-Depth discussion on Topics: •…
Stuart Schlossman
FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS
By Lindsey Shapiro, PhD on 01/03/2023 The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3…
Stuart Schlossman
